Robots and AI: The Future of Cell and Gene Therapy Manufacturing genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
The phase 3 study findings supported belantamab mafodotin as a potential new standard of care in the second line or later among patients with released/refractory multiple myeloma.
The European Commission has granted conditional marketing authorization to talquetamab-tgvs monotherapy for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 3 prior therapies and have demonstrated disease progression on the last therapy.